Novartis has agreed to acquire Myricx Bio for $1.1 billion upfront, with up to $400 million in milestone payments, reinforcing strong pharmaceutical demand for next-generation antibody-drug conjugate ...

VERAXA Biotech (NASDAQ: VRXA) provided a corporate and pipeline update highlighting progress during the first half of ...

VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today provided a company and pipeline update. “In the first six months of 2026, we have made ...

By Karen Roman VERAXA Biotech AG (Nasdaq: VRXA) said it expects BiTAC molecules to be the company’s main value drivers and to dominate its pipeline development in the upcoming years, hence receiving ...

VERAXA Biotech (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Biotechnology investors often focus on clinical milestones, regulatory approvals, and commercial launches. Yet in antibody ...

"Dr. Austin's appointment comes at a transformative period for VERAXA and I'm looking forward to working with him as we enter the next phase in VERAXA's journey,” commented Christoph Antz, Ph.D., CEO ...

Veraxa Biotech AG receives a Sell rating due to overvaluation and post-SPAC merger uncertainty, despite a $77.5M financing package. VRXA’s lead asset, VX-A901 for FLT3-mutated AML, targets a $1.54B ...

ZURICH, July 17, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA” or the "Company"), an emerging leader in designing novel cancer therapies, and Voyager Acquisition Corp., a Cayman Islands ...

Veraxa and Indivumed will work together to develop colorectal antibody drugs. Veraxa Biotech GmbH, Heidelberg, and Indivumed GmbH, Hamburg, announced that they will work together on the discovery and ...

Novel conditionally active T cell engagers sourced from proprietary BiTAC® platform are at the basis of advanced partnering initiatives and development activities ZURICH, SWITZERLAND - July 6, 2026 ...